ProQR Therapeutics (PRQR) Shares Outstanding (Weighted Average) (2013 - 2025)

ProQR Therapeutics has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $5.0 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $5.0 million, down 94.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.0 million (down 94.55% YoY), and the FY2025 annual result was $5.0 million, down 94.55% from the prior year.
• Shares Outstanding (Weighted Average) came in at $5.0 million for Q4 2025 at ProQR Therapeutics, up from $374.1 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $92.0 million in Q4 2024 to a low of $97.77 in Q1 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $339.45 (2023), against an average of $17.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) tumbled 100.0% in 2021 and jumped 69.8% in 2025, its largest moves.
• ProQR Therapeutics' Shares Outstanding (Weighted Average) stood at $85.6 million in 2021, then grew by 0.36% to $86.0 million in 2022, then advanced by 1.41% to $87.2 million in 2023, then grew by 5.54% to $92.0 million in 2024, then tumbled by 94.55% to $5.0 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $5.0 million (Q4 2025), $374.1 (Q3 2025), and $237.71 (Q2 2025), per Business Quant data.